Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, ...

Traws Pharma, Inc. (NASDAQ: TRAW) has announced the retirement of Werner Cautreels, PhD, from his role as Chief Executive Officer, effective March 31, 2025. This leadership transition will coincide ...

Traws Pharma (TRAW) announced the retirement of Werner Cautreels, CEO, effective on or about close of business on March 31 after the company ...

Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimen ...

Traws Pharma, Inc. announced promising results for ratutrelvir, a main protease inhibitor for COVID-19, suggesting it can be administered without ritonavir, potentially reducing the risk of drug ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE ...

Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing FDA ...

Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma”, "Traws” or "the Company”), a clinical ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws ...